Skip to content

Sharing your story: how patient testimonials influence coverage decisions and legislation

Congressional staff say personal stories are helpful and that they rarely get them. Where your GLP-1 coverage story can be used, how to tell it so it's useful, and what to check before you share it.

Updated Sep 26, 2026

If you've fought for GLP-1 coverage, your experience is information that lawmakers and policy staff say they want and seldom receive. In the Congressional Management Foundation's 2015 survey of congressional staff, 79% said a personal story related to a bill or issue is helpful, but only 18% said constituents frequently include one. Staff rated information on how an issue affects the district or state even higher (91% found it helpful), and only 9% said they frequently get it (CMF, Citizen-Centric Advocacy, 2017 (external link)). A specific account of what a coverage gap did to you, where you live, supplies both.

Where your story can be used

  • Legislative testimony or written comment, submitted directly or through an advocacy organization's campaign. Patient groups collect stories for exactly this use (see the role of patient advocacy organizations), and our guide on contacting your lawmakers shows how to fit a story into a call or email.
  • Public comment periods on proposed insurance, Medicare or Medicaid rules. The federal comment process isn't a vote: agencies weigh reasoning and evidence over the number of comments, and official guidance says you may include personal experience where it's relevant (Tips for Submitting Effective Comments (external link)). A detailed account of how a policy affects you is more useful than a signed form letter.
  • Media interviews or op-eds, especially during active policy debates, when journalists are looking for patient voices.
  • Insurer or employer feedback channels, where a specific, documented account of what a coverage gap cost you is harder to set aside than a general complaint.

How to tell a useful story

  1. Be specific. "I was denied coverage despite a qualifying BMI and a documented comorbidity, and the appeal took four months" gives a policymaker something to work with. A general statement of frustration doesn't.
  2. Include the impact, not just the medical facts: lost work time, financial strain, what the delay did to your health.
  3. Keep it short. Testimony and interviews usually have tight time or word limits, and a tightly edited 2-3 minute story is easier to use than a long one.
  4. Decide how identifiable you want to be. You can often share anonymously, by first name only, or fully identified. Advocacy organizations should ask you, not assume, and you don't have to share more than you're comfortable with.

Privacy and safety

Sharing health information publicly is a personal decision with real tradeoffs. Before you submit your story anywhere, find out exactly how it will be used (one-time testimony, or an organization's ongoing media list), whether you can withdraw consent later, and whether you can stay anonymous. Legitimate organizations will be clear about this. If they're vague, be cautious.

This article is general education, not medical, legal, or insurance advice. Coverage rules, appeal rights, and policy details vary by plan and location and change over time. Confirm specifics with your plan, prescriber, or a qualified advisor.

testimonialsstorytellingadvocacypolicy

Was this helpful?

Common questions

Questions people often ask about this topic.

  • Can sharing my story really influence coverage decisions or legislation?

    It can help. In a Congressional Management Foundation survey, 79% of congressional staff said a personal story related to an issue is helpful, but only 18% said constituents frequently include one. That's staff self-report, not proof that stories change votes, but it means a specific, credible account fills a real gap.

  • Where could my story actually be used?

    Legislative testimony or written comment (directly or through an advocacy organization's campaign), public comment periods on proposed insurance, Medicare or Medicaid rules, media interviews or op-eds during active policy debates, and insurer or employer feedback channels. In federal comment periods, agencies weigh reasoning and evidence rather than counting comments, and personal experience can be included where relevant.

  • How do I make my story effective?

    Be specific: details like a denial despite meeting the criteria, or an appeal that took months, give policymakers something to work with. Include the impact (lost work time, financial strain, what the delay did to your health), and keep it short. A tightly edited 2-3 minute account is easier to use than a long one.

  • Do I have to use my real name when I share my story?

    No. You can often share anonymously, by first name only, or fully identified. Legitimate advocacy organizations should ask about your comfort level, not assume, and you don't have to share more than you're comfortable with.

  • What should I check before sharing my health story publicly?

    Find out exactly how it will be used (one-time testimony or an ongoing media list), whether you can withdraw consent later, and whether you can stay anonymous. Legitimate organizations will be clear about all of this. If they're vague, be cautious.

Evidence: For & Against

Both sides of the topic, so you can weigh the evidence yourself.

2Supporting

  • Citizen-Centric Advocacy: The Untapped Power of Constituent Engagement (external link)

    Congressional Management Foundation, 2017 · Reporting · Moderate evidence

    Bradford Fitch, Kathy Goldschmidt, Nicole Folk Cooper (2017)

    2015 congressional staff survey: a personal story related to the bill or issue was rated helpful by 79% of staff but frequently received by only 18%; district/state impact information helpful 91%, frequently received 9%. Staff self-report, not a measure of votes changed.

  • Tips for Submitting Effective Comments (external link)

    Regulations.gov (eRulemaking Program) · Clinical guideline · Strong evidence

    (2026)

    Regulations.gov guidance (hosted by USDA Forest Service): 'The comment process is not a vote'; agencies decide on sound reasoning and evidence, not a majority of votes; 'A single, well-supported comment may carry more weight than a thousand form letters'; commenters may provide personal experience as appropriate.

Revision history

Last updated · 4 revisions recorded.

Show what changed
  1. v4

    Evidence sources 0 → 2

  2. v3

    Common questions revised

  3. v2

    Summary rewritten; Body revised

  4. v1

    Existing article recorded at the start of version history

Improve this page

Community notes

Share helpful experiences and questions. Notes are reviewed before publication and do not replace medical advice.

Loading notes…

    New submissions are currently paused. Existing approved notes remain available.

    Related guides

    • FDA's proposal to keep compounded GLP-1s off the 503B bulks list — and how to comment — In May 2026 the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B compounding bulks list, a decision that affects how compounded GLP-1s can be made. The public comment period closed July 30, 2026, and as of late September 2026 the FDA has not published a final determination. This guide explains the proposal, why it matters for access, and what you can still do.
    • The Treat and Reduce Obesity Act (H.R. 4231 / S. 1973): what it is and why it matters — TROA is the main federal bill aimed at ending Medicare's exclusion of obesity medications. It was first introduced in 2013 and has been reintroduced with bipartisan support in later Congresses, but it hasn't passed. This guide explains what it would change.
    • The push to get Medicare to cover GLP-1 medications for obesity — Medicare is legally barred from covering weight-loss drugs, yet it covers the same medications for diabetes or heart disease. As of September 2026, a temporary CMS demonstration called the GLP-1 Bridge lets eligible beneficiaries get certain GLP-1s for about $50 a month while the underlying exclusion stays in place. This guide explains why the gap exists, what the Bridge does and doesn't change, and how patients and advocates are pushing for a permanent fix.
    • How GLP-1 coverage mandates differ by state — A few states require some insurance plans to cover obesity treatment, including GLP-1 medications; most don't. This guide covers how state mandates work, why they skip most people with job-based insurance, and how to find out what your state requires.
    • How to contact your lawmakers about GLP-1 coverage: a step-by-step guide — Congressional staff say individualized contact from constituents sways undecided lawmakers, but most messages leave out what staff find useful. This guide shows how to find your federal and state legislators, match your ask to the right level of government (TROA, the Medicare fix, state mandates, Medicaid), pick a channel, tell your story, and follow up, with a call script and email template.
    • Obesity Action Coalition (official site) — The official site of the Obesity Action Coalition, a national patient advocacy nonprofit: education, community support and advocacy resources for people affected by obesity.